Cholestech's lipid and liver function test launched in the US:
This article was originally published in Clinica
Hayward, California-based Cholestech is rolling out its Lipid Profile ALT test cassette in the US after the FDA granted CLIA waived status for the product, a test for liver function. The device enables healthcare providers to test a patient's lipid profile and alanine aminotransferase (ALT) levels simultaneously, giving results within five minutes. ALT is the most common marker for liver damage. The test can be performed in the doctor's office lab with just a single fingerstick. It is designed to allow doctors to monitor the patient's use of certain drugs, particularly statins, though lipid and liver monitoring are recommended when using a variety of other prescription drugs. Tests are performed before treatment initiation to establish a baseline level and periodically thereafter to help determine the appropriate therapeutic course of action.